Tag: Biotech and Pharma

U.S. drugmaker Eli Lilly (LLY) is in advanced talks to acquire ​biotech firm Kelonia Therapeutics for more than $2 ‌billion, the Wall Street Journal reported on Sunday.

Abbott Laboratories reported first-quarter earnings in line with expectations and revenue above forecasts on Wednesday, but shares slipped after the medical device maker issued soft second-quarter profit guidance.

Novo Nordisk is partnering with OpenAI to “bring new and better treatment options to patients faster,” the Danish drugmaker said Tuesday.

Johnson & Johnson (JNJ) has reinvented itself several times in recent years. In 2021, it was best known as the developer of a Covid vaccine.

Σε συμφωνία με την Janssen Global Services ήρθε η Lavipharm A.E. για την απόκτηση των δικαιωμάτων του συνταγογραφούμενου διαδερμικού επιθέματος DUROGESIC

Revolution Medicines’ drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial, almost doubling the typical length of survival and slashing the risk of death by 60% versus chemotherapy, the company said Monday.

After years of trying to lose weight “the right way,” Jane Zuckerman realized that “putting in the work just wasn’t enough.”

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street.

Novo Nordisk rose as much as 4% after England’s drug price watchdog recommended the use of its best-selling drug Wegovy to prevent heart attacks and strokes, marking the first GLP-1 backed for this use in the country.

Eli Lilly has agreed to buy clinical-stage company Centessa Pharmaceuticals for an initial payment of about $6.3 billion in a deal that expands the drugmaker’s neuroscience portfolio and capabilities into sleep medicine.

Novo Nordisk will launch a discounted subscription plan for U.S. Wegovy patients paying for the drug themselves, offering monthly ‌prices up to nearly 30% below its standard rate as it tries to widen access and regain ground from Eli Lilly in the booming obesity-drug market.

Novartis is planning to buy U.S.-based biotech Excellergy for up to $2 billion, betting on a next-generation allergy treatment that may prove to work faster and better than anything currently on the market.

Merck to pay a 6% premium to buy the outstanding shares of Terns Pharmaceuticals, which is developing an oral treatment for leukemia.

Ισχυρή επίδοση κατέγραψε η Lavipharm το 2025 σύμφωνα με τα μη ελεγμένα χρηματοοικονομικά στοιχεία που δημοσιοποίησε η εταιρεία.

Compounded weight-loss drugs that contain vitamin B12 and the main ingredient in Eli Lilly’s (LLY) ‌Zepbound could present health risks to consumers due to a previously unidentified impurity caused in the preparation, the U.S. drugmaker said in a public letter released on Thursday.

Novo Nordisk A/S plans to sell its weight-loss drugs on Hims & Hers Health Inc.’s platform, according to a person familiar with the matter, ending a highly public feud between the two companies that spiraled into a legal battle last month.

Novartis said on Wednesday it intends to build a radioligand therapy manufacturing site in Texas, ‌expanding its U.S. footprint with what will be ‌its first such facility in the state and fifth nationwide.

GSK (GSK) has agreed to pay $950 million in cash for Canadian biotech 35Pharma, it said on Wednesday, marking the second major deal new CEO Luke Miels has struck to accelerate development of new medicines at the British drugmaker.

Fresenius Medical Care AG (FMS) reported fourth-quarter adjusted earnings per share of EUR 1.44, beating expectations.

Hims & Hers Health (HIMS) stock fell after the telehealth company posted mixed quarterly results and issued a weak outlook for the current quarter.